+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route Of Administration, End User, Fracture Type - Global Forecast to 2030- Product Image
Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route Of Administration, End User, Fracture Type - Global Forecast to 2030- Product Image
Sale

Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route Of Administration, End User, Fracture Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 186 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336746
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Osteoporosis Therapy & Fracture Healing Market grew from USD 14.97 billion in 2024 to USD 16.28 billion in 2025. It is expected to continue growing at a CAGR of 8.56%, reaching USD 24.50 billion by 2030.

Shaping the Future of Osteoporosis and Fracture Care

Osteoporosis remains a pervasive healthcare challenge worldwide, exerting a profound impact on patient quality of life and healthcare systems. Despite significant advances in diagnosis and management, gaps persist in therapeutic access, adherence, and fracture prevention strategies. Patients and providers alike seek robust solutions that not only strengthen bone density but also accelerate fracture healing and reduce long-term disability.

This executive summary distills the most critical developments influencing the anti-osteoporosis market and fracture healing therapies. By examining regulatory shifts, tariff impacts, segmentation dynamics, regional trends, and leading industry players, this report offers a panoramic perspective on where the field stands today. With an emphasis on both innovation and practical implementation, these insights empower decision-makers to align clinical objectives with commercial realities. Whether you are evaluating emerging biologics or refining patient support programs, this summary illuminates the pathways to sustained success in a rapidly changing landscape.

Transformative Shifts Reshaping Bone Health Management

Over the past decade, the anti-osteoporosis domain has witnessed a series of transformative shifts that continue to redefine treatment paradigms. Advances in monoclonal antibody therapies have introduced potent mechanisms of action, targeting key pathways in bone resorption and formation. At the same time, refinements in hormone replacement protocols and selective estrogen receptor modulators have optimized risk-benefit profiles, particularly among postmenopausal populations.

In parallel, delivery platforms have diversified to include both intravenous and subcutaneous approaches that address patient convenience and adherence concerns. Oral bisphosphonates remain foundational, yet their scheduling complexities have fueled interest in less frequent dosing regimens. Furthermore, the integration of digital health tools for monitoring bone density changes and capturing real-world patient outcomes is enhancing personalized care. Together, these shifts underscore a dynamic environment in which scientific innovation, patient experience, and health economics converge to shape future opportunities.

Assessing the Ripple Effects of 2025 US Tariffs on Treatment Access

Policy changes enacted in early 2025, particularly the imposition of cumulative tariffs on key therapeutic imports, have reshaped pricing and access dynamics within the United States. Many advanced biologics and novel analogues were subject to elevated duties, placing upward pressure on manufacturer costs. As a result, supply chains adjusted shipping routes and sourcing strategies to mitigate tariff burdens and protect margin integrity.

These policy measures have compelled healthcare stakeholders to reevaluate procurement models, negotiate differentiated pricing agreements, and explore domestic manufacturing partnerships. Consequently, the cost of certain monoclonal antibodies and parathyroid hormone analogues saw a notable rise, prompting payers to demand more rigorous value-based contracting terms. At the same time, price-sensitive segments have demonstrated increased uptake of oral bisphosphonates and generic hormone therapies. Through proactive stakeholder collaboration, the industry is navigating these headwinds by balancing affordability with sustained investment in research and development.

Unveiling Segmentation Dynamics Driving Therapeutic Strategies

A nuanced analysis by therapy type reveals a multilayered landscape of patient needs and commercial potential. Within bisphosphonates, alendronate continues to anchor first-line interventions, while ibandronate and risedronate deliver alternative dosing intervals. Zoledronic acid distinguishes itself through annual infusion protocols that simplify adherence. Hormone replacement therapy bifurcates into combined hormone regimens that optimize fracture prevention and standalone estrogen formulations preferred by individuals prioritizing symptom relief. Monoclonal antibody treatments have split between denosumab’s dual indications as marketed under Prolia and Xgeva and the anabolic activity of romosozumab. Parathyroid hormone analogues including abaloparatide and teriparatide capitalize on bone formation pathways, and selective estrogen receptor modulators such as bazedoxifene and raloxifene offer additional post-menopausal fracture risk reduction.

Routes of administration further stratify opportunities. Injectable therapies delivered either intravenously or subcutaneously cater to patients seeking less frequent dosing, while oral options remain integral to broad outpatient access. End users span homecare settings where self-administration is feasible, hospitals that manage acute fracture interventions, and specialty clinics delivering targeted osteoporosis programs. Lastly, fracture type underscores clinical urgency and resource allocation: hip fractures demand surgical and rehabilitative coordination, spinal compression fractures require sophisticated imaging and vertebral augmentation techniques, and wrist fractures often involve outpatient orthopaedic follow-up. By weaving these dimensions together, stakeholders can tailor development and commercialization strategies to meet precise clinical and economic requirements.

Regional Dynamics Shaping Global Therapy Adoption

Regional performance in anti-osteoporosis and fracture healing therapies is shaped by divergent healthcare infrastructures, reimbursement models, and demographic profiles. In the Americas, expansive insurance networks and established biologics markets drive robust adoption of monoclonal antibodies and parathyroid hormone analogues, though cost scrutiny remains vigorous among public payers. Europe, Middle East & Africa exhibit variable uptake: Western Europe favors innovation through value-based agreements, whereas certain EMEA markets prioritize generic and biosimilar options to contain budgets. Asia-Pacific demonstrates rapid growth potential fueled by aging populations in Japan, South Korea, and China, alongside increasing awareness in emerging markets such as India and Southeast Asia. Local production partnerships and regulatory harmonization efforts further influence therapeutic accessibility across these regions.

Moreover, each region’s fracture epidemiology informs resource allocation. The prevalence of hip and spinal fractures in northern latitudes drives surgical volume and postoperative care enhancements in Americas and Europe. Meanwhile, wrist fractures among younger cohorts prompt early intervention protocols in select Asia-Pacific markets. Recognizing these regional nuances enables more precise alignment of product launches, pricing strategies, and patient support initiatives with market realities.

Competitive Spotlight on Leading Osteoporosis Therapy Innovators

Industry competition centers on pioneering molecules and differentiated delivery systems. Amgen’s Prolia remains a cornerstone in anti-resorptive therapy, leveraging a strong patient support infrastructure. Novartis and its alliance partners drive growth in romosozumab, highlighting the appeal of anabolic mechanisms. Eli Lilly’s teriparatide franchise maintains steady demand among high-risk patients, while Radius Health’s abaloparatide positions itself as a convenient alternative with tailored dosing schedules. UCB and Pfizer continue to refine their biosimilar bisphosphonate portfolios, challenging originator brands on price and access. Additionally, next-generation selective estrogen receptor modulators and hormone replacement formulations from specialty biotech firms inject fresh competition into established segments.

Beyond molecular innovation, companies invest in digital adherence platforms, patient education hubs, and integrated fracture liaison services. These value-added offerings differentiate brand experiences and foster long-term loyalty. Collaborative research agreements and strategic licensing deals further amplify pipeline potential, with mid-size players partnering with contract manufacturing organizations to scale production quickly. As competition intensifies, the ability to demonstrate real-world outcomes and cost offsets will prove decisive in capturing market share.

Strategic Imperatives for Industry Leadership in Bone Care

Industry leaders should prioritize patient-centric models that integrate digital tools for monitoring bone mineral density and medication adherence. By embedding telehealth consultations with remote DXA scan reporting, organizations can enhance care continuity and patient engagement. In parallel, forging partnerships with payers to develop outcome-driven contracts will align reimbursement with therapeutic value, ensuring sustainable access for high-cost biologics and analogues.

Manufacturers must also diversify their supply chains to mitigate further tariff exposure, exploring localized production in key markets and securing multiple sourcing arrangements for active pharmaceutical ingredients. Concurrently, expanding fracture liaison services in hospitals and specialty clinics can reduce refracture rates and lower total cost of care. Finally, investing in targeted education campaigns for primary care physicians and orthopaedic surgeons about the latest evidence in anabolic therapies and selective estrogen receptor modulators will accelerate adoption and optimize patient outcomes.

Robust Methodology Underpinning Our Comprehensive Analysis

This analysis synthesizes primary research gathered through structured interviews with endocrinologists, orthopaedic surgeons, payers, and patient advocacy groups. Secondary sources include peer-reviewed journals, regulatory agency publications, patent filings, and corporate financial disclosures. Data were cross-verified against public reimbursement databases and device registries to ensure consistency and reliability.

Segmentation was applied rigorously across therapy types, routes of administration, end-user settings, and fracture categories to uncover nuanced adoption patterns. Regional overlays integrated macroeconomic indicators and demographic projections without extrapolating future growth rates. Competitive landscaping leveraged therapeutic pipeline databases and licensing announcements to map collaboration networks and anticipate strategic trajectories. Quality control measures included editorial reviews, statistical validation of quantitative inputs, and peer audits by subject-matter experts.

Synthesis and Forward Momentum in Osteoporosis Management

The convergence of scientific innovation, regulatory shifts, and market dynamics underscores a pivotal moment in anti-osteoporosis care. As advanced monoclonal antibodies and anabolic analogues mature, stakeholders face the dual imperatives of demonstrating cost effectiveness and optimizing patient experience. Tariff-induced pressures have catalyzed procurement ingenuity, while segmentation and regional nuances continue to inform tailored strategies.

Looking ahead, the industry’s capacity to blend digital health technologies with traditional treatment frameworks will determine its success in closing therapeutic gaps. By leveraging the insights outlined above, decision-makers can refine investment priorities, enhance stakeholder collaboration, and ultimately drive improved bone health outcomes across diverse patient populations.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Bisphosphonates
      • Alendronate
      • Ibandronate
      • Risedronate
      • Zoledronic Acid
    • Hormone Replacement Therapy
      • Combined Hormone Therapy
      • Estrogen Therapy
    • Monoclonal Antibodies
      • Denosumab
        • Prolia
        • Xgeva
      • Romosozumab
    • Parathyroid Hormone Analogues
      • Abaloparatide
      • Teriparatide
    • Selective Estrogen Receptor Modulators
      • Bazedoxifene
      • Raloxifene
  • Route Of Administration
    • Injectable
      • Intravenous
      • Subcutaneous
    • Oral
  • End User
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Fracture Type
    • Hip
    • Spinal
    • Wrist
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Amgen Inc.
  • Stryker Corporation
  • Medtronic plc
  • Novartis AG
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Orthofix Medical Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Therapy Type
8.1. Introduction
8.2. Bisphosphonates
8.2.1. Alendronate
8.2.2. Ibandronate
8.2.3. Risedronate
8.2.4. Zoledronic Acid
8.3. Hormone Replacement Therapy
8.3.1. Combined Hormone Therapy
8.3.2. Estrogen Therapy
8.4. Monoclonal Antibodies
8.4.1. Denosumab
8.4.1.1. Prolia
8.4.1.2. Xgeva
8.4.2. Romosozumab
8.5. Parathyroid Hormone Analogues
8.5.1. Abaloparatide
8.5.2. Teriparatide
8.6. Selective Estrogen Receptor Modulators
8.6.1. Bazedoxifene
8.6.2. Raloxifene
9. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Intravenous
9.2.2. Subcutaneous
9.3. Oral
10. Anti-Osteoporosis Therapy & Fracture Healing Market, by End User
10.1. Introduction
10.2. Homecare
10.3. Hospitals
10.4. Specialty Clinics
11. Anti-Osteoporosis Therapy & Fracture Healing Market, by Fracture Type
11.1. Introduction
11.2. Hip
11.3. Spinal
11.4. Wrist
12. Americas Anti-Osteoporosis Therapy & Fracture Healing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Anti-Osteoporosis Therapy & Fracture Healing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Anti-Osteoporosis Therapy & Fracture Healing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Amgen Inc.
15.3.2. Stryker Corporation
15.3.3. Medtronic plc
15.3.4. Novartis AG
15.3.5. Merck & Co., Inc.
15.3.6. Teva Pharmaceutical Industries Ltd.
15.3.7. Eli Lilly and Company
15.3.8. Orthofix Medical Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET MULTI-CURRENCY
FIGURE 2. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET MULTI-LANGUAGE
FIGURE 3. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 71. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 72. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 73. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 74. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 75. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 76. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 77. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 79. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. CANADA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 82. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 83. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 84. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 85. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 86. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 87. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 88. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. MEXICO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 137. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 139. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 140. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 142. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 143. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 144. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 146. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. GERMANY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 153. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 154. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 155. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 157. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. FRANCE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 161. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 170. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 171. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 172. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 173. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 174. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 175. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 176. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 177. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 179. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. ITALY ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 181. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 182. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 183. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 184. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 185. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 186. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 187. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 188. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 190. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. SPAIN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 192. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 194. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 205. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 214. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 215. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 216. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 225. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 227. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 228. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 229. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 230. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 231. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 232. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 234. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. DENMARK ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 247. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 248. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 249. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
TABLE 250. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 251. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2030 (USD MILLION)
TABLE 252. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2030 (USD MILLION)
TABLE 253. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 254. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 256. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 257. QATAR ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2030 (USD MILLION)
TABLE 258. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 259. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2030 (USD MILLION)
TABLE 260. FINLAND ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING M

Companies Mentioned

The companies profiled in this Anti-Osteoporosis Therapy & Fracture Healing market report include:
  • Amgen Inc.
  • Stryker Corporation
  • Medtronic plc
  • Novartis AG
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Orthofix Medical Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.28 Billion
Forecasted Market Value ( USD ) by 2030 $ 24.5 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned9

Related Topics

Related Reports

Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Anti Osteoporosis Therapy and Fracture Healing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Osteoporosis Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033 - Product Image

Osteoporosis Drugs Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033

  • Report
  • 200 Pages
  • Global
From
Osteoporosis Treatment Market Report 2025 - Product Image

Osteoporosis Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Osteoporosis Drugs Market by Drug Class, Route of Administration, Dosage Form, Distribution Channel, End User, Patient Gender - Global Forecast to 2030 - Product Image

Osteoporosis Drugs Market by Drug Class, Route of Administration, Dosage Form, Distribution Channel, End User, Patient Gender - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2024-2032 - Product Image

Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.